Allarity Therapeutics, Inc. ALLR
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell's sensitivity to a specific cancer therapeutic. Once defined, the DRP® gene expression signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity, and by extension, to identify those patients who may then be most likely to receive benefit from that specific anti-cancer therapeutic. We have developed and published DRP® signatures for dozens of anti-cancer therapeutics. Ideally, by using DRP to identify the patients most likely to benefit clinically from a given therapeutic, clinical development of that therapeutic can be focused on a smaller, more responsive patient population, which would allow for smaller, cheaper and quicker trials while also enhancing the probability of clinical and regulatory success for that therapeutic. Historically, we have generated DRP signatures for numerous anti-cancer therapeutics and had in-licensed numerous assets for DRP-guided development, including Liposomal CisPlatin (LiPlaCis), Irofulven and dovitinib as well as the novel PARP/tankyrase inhibitor, stenoparib.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $320.0K | $0 | — | — | — | — | — |
| Gross profit | — | — | — | -$2.3M | — | — | — |
| R&D | $6.6M | $6.1M | $7.1M | $6.9M | $14.2M | $4.2M | — |
| SG&A | $6.3M | $11.4M | $10.0M | $10.0M | $12.4M | $4.1M | — |
| Total operating expenses | $12.9M | $27.2M | $17.1M | $34.5M | $26.6M | $8.3M | — |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M | -$26.6M | -$8.3M | — |
| Interest expense | $185.0K | $653.0K | $498.0K | $223.0K | $1.3M | $93.0K | — |
| Pre-tax income | -$11.2M | -$24.9M | -$11.8M | -$17.6M | -$26.5M | -$6.4M | — |
| Income tax | $0 | $381.0K | $83.0K | $1.5M | $133.0K | $198.0K | — |
| Net income | -$11.2M | -$24.5M | -$11.9M | -$16.1M | -$26.6M | -$6.6M | — |
| EPS, basic | -0.78 | -15.65 | -6,031.31 | -3,093.42 | -4.19 | -2.03 | — |
| EPS, diluted | — | — | -10.26 | -3,093.42 | -4.19 | — | — |
| Shares, diluted (wtd. avg.) | 14.4M | 1.6M | 3,385 | 6,805 | 6.4M | 3.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.7M | $19.5M | $166.0K | $2.0M | $19.6M | $298.0K | — |
| Total current assets | $17.9M | $22.3M | $2.0M | $5.0M | $21.4M | $1.7M | — |
| Property, plant and equipment | $330.0K | $309.0K | $20.0K | $21.0K | $8.0K | $21.0K | — |
| Other intangibles | — | $0 | $9.9M | $9.5M | $28.1M | $30.5M | — |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | $49.6M | $33.4M | — |
| Accounts payable | $4.3M | $4.2M | $8.4M | $6.3M | $698.0K | $2.1M | — |
| Short-term debt | — | — | $250.0K | — | — | — | — |
| Total current liabilities | $8.4M | $10.8M | $14.2M | $11.2M | $20.7M | $5.5M | — |
| Long-term debt | — | — | $2.7M | $2.6M | — | — | — |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | $30.8M | $9.0M | — |
| Retained earnings | -$130.2M | -$119.0M | -$94.5M | -$82.5M | -$66.5M | -$39.8M | — |
| Total equity | $9.8M | $11.8M | -$2.8M | -$113.0K | $18.2M | $24.4M | $20.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.8M | -$17.4M | -$12.7M | -$16.8M | -$14.9M | -$7.3M | — |
| Depreciation and amortisation | — | $9.0K | $37.0K | $60.0K | $106.0K | $46.0K | — |
| Stock-based compensation | $482.0K | $71.0K | -$71.0K | $1.8M | $6.4M | $616.0K | — |
| Capital expenditure | $8.0K | $298.0K | $0 | $18.0K | — | $3.0K | — |
| Investing cash flow | -$8.0K | -$298.0K | $0 | $791.0K | $1.0M | -$3.0K | — |
| Financing cash flow | $10.6M | $36.8M | $11.0M | -$1.3M | $33.8M | $6.0M | — |
| Buybacks | $3.2M | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-010310.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $320.0K |
| Gross profit | — | — | — | -$2.3M | — | — | — |
| Net income | — | -$6.6M | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |